Rapid and durable response demonstrated in the first placebo-controlled study of DMT for depression

Written By Guest User

Small Pharma announced the results of its Phase 2a clinical trial, treating moderate to severe Major Depressive Disorder (MDD) with DMT-assisted therapy.

The trial carries special significance, as it is the first-ever clinical trial attempting to treat a mental health disorder with DMT, the shorter-acting chemical cousin to psilocybin.

Guest User
Previous

Australia becomes the first country to introduce psychedelic novel therapies to its medical healthcare
Next

Second successful Phase 3 trial of MDMA-assisted therapy for PTSD